The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for unresectable stage IV malignant melanoma (MM): MC1371 (NCT02020707).
 
Matthew Stephen Block
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Immune Design; Marker, Inc.; Merck; Pharmacyclics
 
Vera J. Suman
No Relationships to Disclose
 
Wendy Kay Nevala
No Relationships to Disclose
 
Heidi Diann Finnes
No Relationships to Disclose
 
Jill Schimke
No Relationships to Disclose
 
Carrie Strand
No Relationships to Disclose
 
Anastasios Dimou
Honoraria - Roche/Genentech
 
Lisa A. Kottschade
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Yiyi Yan
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
Craig Hocum
No Relationships to Disclose
 
Svetomir Markovic
Research Funding - Bristol-Myers Squibb; Seagen; Vavotar Life Sciences
 
Robert R. McWilliams
Consulting or Advisory Role - Merrimack (Inst); Zeno Pharmaceuticals
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); PRISM BioLab (Inst); Sanofi (Inst)